Luca Cumitini, Ailia Giubertoni, Lidia Rossi, Domenico D'Amario, Leonardo Grisafi, Paola Abbiati, Fabrizio D'Ascenzo, Gaetano Maria De Ferrari, Giuseppe Patti
{"title":"Stratification of Early Arrhythmic Risk in Patients Admitted for Acute Coronary Syndrome: The Role of the Machine Learning-Derived “PRAISE Score”","authors":"Luca Cumitini, Ailia Giubertoni, Lidia Rossi, Domenico D'Amario, Leonardo Grisafi, Paola Abbiati, Fabrizio D'Ascenzo, Gaetano Maria De Ferrari, Giuseppe Patti","doi":"10.1002/clc.70035","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The PRAISE (PRedicting with Artificial Intelligence riSk aftEr acute coronary syndrome) score is a machine learning-based model for predicting 1-year adverse cardiovascular or bleeding events in patients with acute coronary syndrome (ACS). Its role in predicting arrhythmic complications in ACS remains unknown.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Atrial fibrillation (AF) and ventricular arrhythmias (VA) were recorded by continuous electrocardiographic monitoring until discharge in a cohort of 365 participants with ACS prospectively enrolled. We considered two separate timeframes for VA occurrence: ≤ 48 and > 48 h. The objective was to evaluate the ability of the PRAISE score to identify ACS patients at higher risk of in-hospital arrhythmic complications.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>ROC curve analysis indicated a significant association between PRAISE score and risk of both AF (AUC 0.89, <i>p</i> = 0.0001; optimal cut-off 5.77%) and VA (AUC 0.69, <i>p</i> = 0.0001; optimal cut-off 2.17%). Based on these thresholds, high/low AF PRAISE score groups and high/low VA PRAISE score groups were created, respectively. Patients with a high AF PRAISE score more frequently developed in-hospital AF (19% vs. 1%). Multivariate analysis showed a high AF PRAISE score risk as an independent predictor of AF (HR 4.30, <i>p</i> = 0.016). Patients with high VA PRAISE scores more frequently developed in-hospital VA (25% vs. 8% for VA ≤ 48 h; 33% vs. 3% for VA > 48 h). Multivariate analysis demonstrated a high VA PRAISE score risk as an independent predictor of both VA ≤ 48 h (HR 2.48, <i>p</i> = 0.032) and VA > 48 h (HR 4.93, <i>p</i> = 0.014).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The PRAISE score has a comprehensive ability to identify with high specificity those patients at risk for arrhythmic events during hospitalization for ACS.</p>\n </section>\n </div>","PeriodicalId":10201,"journal":{"name":"Clinical Cardiology","volume":"47 12","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.70035","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.70035","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The PRAISE (PRedicting with Artificial Intelligence riSk aftEr acute coronary syndrome) score is a machine learning-based model for predicting 1-year adverse cardiovascular or bleeding events in patients with acute coronary syndrome (ACS). Its role in predicting arrhythmic complications in ACS remains unknown.
Methods
Atrial fibrillation (AF) and ventricular arrhythmias (VA) were recorded by continuous electrocardiographic monitoring until discharge in a cohort of 365 participants with ACS prospectively enrolled. We considered two separate timeframes for VA occurrence: ≤ 48 and > 48 h. The objective was to evaluate the ability of the PRAISE score to identify ACS patients at higher risk of in-hospital arrhythmic complications.
Results
ROC curve analysis indicated a significant association between PRAISE score and risk of both AF (AUC 0.89, p = 0.0001; optimal cut-off 5.77%) and VA (AUC 0.69, p = 0.0001; optimal cut-off 2.17%). Based on these thresholds, high/low AF PRAISE score groups and high/low VA PRAISE score groups were created, respectively. Patients with a high AF PRAISE score more frequently developed in-hospital AF (19% vs. 1%). Multivariate analysis showed a high AF PRAISE score risk as an independent predictor of AF (HR 4.30, p = 0.016). Patients with high VA PRAISE scores more frequently developed in-hospital VA (25% vs. 8% for VA ≤ 48 h; 33% vs. 3% for VA > 48 h). Multivariate analysis demonstrated a high VA PRAISE score risk as an independent predictor of both VA ≤ 48 h (HR 2.48, p = 0.032) and VA > 48 h (HR 4.93, p = 0.014).
Conclusion
The PRAISE score has a comprehensive ability to identify with high specificity those patients at risk for arrhythmic events during hospitalization for ACS.
背景:PRAISE(人工智能预测急性冠脉综合征后风险)评分是一种基于机器学习的模型,用于预测急性冠脉综合征(ACS)患者1年内的不良心血管或出血事件。它在预测ACS的心律失常并发症中的作用尚不清楚。方法:前瞻性纳入365例ACS患者,通过连续心电图监测记录房颤(AF)和室性心律失常(VA)直至出院。我们考虑了两个独立的VA发生时间框架:≤48小时和bb0 48小时。目的是评估PRAISE评分识别院内心律失常并发症高风险ACS患者的能力。结果:ROC曲线分析显示,PRAISE评分与两种AF的风险均有显著相关性(AUC 0.89, p = 0.0001;最佳临界值5.77%)和VA (AUC 0.69, p = 0.0001;最佳截止点2.17%)。根据这些阈值,分别创建高/低AF PRAISE评分组和高/低VA PRAISE评分组。房颤PRAISE评分高的患者更容易发生院内房颤(19%对1%)。多因素分析显示,高AF PRAISE评分风险是AF的独立预测因子(HR 4.30, p = 0.016)。VA PRAISE评分高的患者更容易发生院内VA (25% vs. VA≤48 h的患者为8%;33% vs. 3% VA bb0(48小时)。多因素分析表明,VA PRAISE评分高的风险是VA≤48 h (HR 2.48, p = 0.032)和VA bb0 48 h (HR 4.93, p = 0.014)的独立预测因子。结论:PRAISE评分对ACS住院期间存在心律失常风险的患者具有综合、高特异性的识别能力。
期刊介绍:
Clinical Cardiology provides a fully Gold Open Access forum for the publication of original clinical research, as well as brief reviews of diagnostic and therapeutic issues in cardiovascular medicine and cardiovascular surgery.
The journal includes Clinical Investigations, Reviews, free standing editorials and commentaries, and bonus online-only content.
The journal also publishes supplements, Expert Panel Discussions, sponsored clinical Reviews, Trial Designs, and Quality and Outcomes.